Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prostate cancer in UK set to overtake lung cancer:

This article was originally published in Clinica

Executive Summary

Prostate cancer is set to overtake lung cancer as the most common form of cancer diagnosed in the UK. By 2018, the Institute of Cancer Research warns that prostate cancer will affect one in four men. The ICR says that more money should be spent on research into the disease. At present, only £1 million (S1.6 million) is spent each year, compared with £16 million for breast cancer or £15 million on AIDS. A mass screening plan using the PSA (prostate specific antigen) test was ruled out by the National Health Service after researchers decided that the test was too unreliable.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT085992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel